Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy
Cells · 15.06.2026 · 15 (12) · 1087
DOI: 10.3390/cells15121087 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 15.06.2026. Verfasst von Tadeusz Strózik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Disulfidptosis, Protein Processing, Post-Translational, Immunotherapy, Adoptive. Die Arbeit nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, LEK-AM Pharmaceutical Company Ltd..
Abstract (Originalsprache)
Glioblastoma (GB) remains one of the most therapy-resistant solid tumors, characterized by profound metabolic plasticity, intratumoral heterogeneity, and a highly immunosuppressive microenvironment. While immunotherapies such as chimeric antigen receptor T (CAR-T) cells have shown promise in hematological malignancies, their efficacy in GB has been limited. Emerging evidence suggests that tumor-specific metabolic dependencies and post-translational modifications (PTMs) may represent exploitable vulnerabilities. This review discusses disulfidptosis, a recently described form of regulated cell death driven by disulfide stress under conditions of limited reducing capacity, as a context-dependent metabolic–redox vulnerability in GB. We further discuss how altered protein glycosylation and glycocalyx architecture in glioblastoma regulate cell survival, death signaling, and immune recognition. Particular emphasis is placed on the glycosylation of surface antigens targeted by CAR-T cells, including EGFR/EGFRvIII, IL-13Rα2, mesothelin, B7-H3, HER2, and GD2, and on how glycan-dependent epitope accessibility may limit therapeutic efficacy. Finally, we distinguish disulfidptosis, whose direct relevance to CAR-T-cell responses remains to be established, from glycosylation and glycocalyx remodeling as more direct determinants of target–antigen accessibility and immune recognition. Therapeutic strategies addressing these vulnerabilities may provide rational opportunities to improve CAR-T-based and combinatorial therapies for GB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland.
- Department of Research and Development, LEK-AM Pharmaceutical Company Ltd., Inwestycyjna 7 St., 95-050 Konstantynow Lodzki, Poland.
- Department of Tumor Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland.
- Student Scientific Circle at the Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland.
ORCID-Profile: Tadeusz Strózik, Adrianna Rutkowska, Tomasz Wasiak, Piotr Rieske
Förderung
- Medical University of Lodz
- LEK-AM Pharmaceutical Company Ltd.
Zitieren
APA
Strózik, T., Rutkowska, A., Wasiak, T., Ciunowicz, D., Rieske, P., Szczepaniak, N., & Stoczyńska-Fidelus, E. (2026). Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy. Cells, 15(12), 1087. https://doi.org/10.3390/cells15121087
Vancouver
Strózik T, Rutkowska A, Wasiak T, Ciunowicz D, Rieske P, Szczepaniak N, et al. Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy. Cells. 2026;15(12):1087. doi:10.3390/cells15121087
BibTeX
@article{Strzik2026,
author = {Strózik, Tadeusz and Rutkowska, Adrianna and Wasiak, Tomasz and Ciunowicz, Damian and Rieske, Piotr and Szczepaniak, Natalia and Stoczyńska-Fidelus, Ewelina},
title = {Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy},
journal = {Cells},
year = {2026},
volume = {15},
number = {12},
pages = {1087},
doi = {10.3390/cells15121087}
}
EUVIMED